Immix Biopharma Investor Presentation Deck

ImmixBio Pipeline Summary Stage Clinical Preclinical Tx Type CAR-T TSTX CAR-T CAR-T TSTX TSTX Candidate NXC-201 target BCMA ¡MX-110 TME Normalization™ Technology NXC-301 NXC-401 iMX-111 iMX-120 Indication Multiple Myeloma AL Amyloidosis Soft Tissue Sarcoma Solid Tumors, Colorectal + Tislelizumab (anti-PD-1) ALL, LBCL, MCL AML Colorectal Cancer Inflammatory Bowel Disease Preclinical Phase 1b/2a Ongoing Phase 1b/2a Ongoing Phase 1b/2a Ongoing Phase 1 Phase 1b/2a Ongoing Preclinical Preclinical Preclinical Preclinical Phase 2 Phase 3 Approval Collaboration BeiGene Progress 63 patients treated 95% overall response rate US FDA Orphan Drug Designation (ODD) for Multiple Myeloma Granted . 9 patients treated in relapsed/refractory AL Amyloidosis • 100% overall response rate • 67% complete response rate . ●●● IMMIX S BIOPHARMA US FDA Orphan Drug Designation (ODD) for AL Amyloidosis Granted US FDA Orphan Drug Designation (ODD) for STS Granted US FDA Rare Pediatric Disease Designation (RPDD) Granted Zero drug-related SAES CMC: 7 GMP batches manufactured to-date In preclinical development EXPAND technology In preclinical development EXPAND technology Tissue Specific Biologic™ Targeted biomarker GLUT1 overexpressed in stage 3/4 colorectal cancer and additional tumor types Tissue Specific Biologic™ 12-month end-to-end clinical trial leading to potential approval in multi billion-dollar indication Global Rights **** +00 do BIOPHARMA IMMIX O IMMIX ... 60 BIOPHARMA • +00 • *00 000 59 •[00 *** sp 00 5 O 00 +00 50 0 *** IMMIX BIOPHARMA IMMIX BIOPHARMA IMMİX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA IMMİX BIOPHARMA 20 Note: 95% overall response rate in multiple myeloma isf or patients without prior BCMA targeted therapies. Treatment. Source: Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023.. Lebel E, et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

View entire presentation